Drugs / Recombinant HIV I Clade B Measles Vaccine Vector
Recombinant HIV I Clade B Measles Vaccine Vector
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01320176 | Oct 2010 → Nov 2011 | HIV infectious disease | Institut Pasteur | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant HIV I Clade B Measles Vaccine Vector | “An Open-label, Phase I, Dose-escalation and Safety Study of Two Intramuscular Injections of a Dose of 2.9 Log or 4 Log CCID50 of the Recombinant HIV I Clade B Measles Vaccine...” NCT01320176 ↗ |
| Modality | Vaccine | “investigational clade B HIV vaccine” NCT01320176 ↗ |
| Route | Intramuscular | “The vaccine will be administered by intramuscular route” NCT01320176 ↗ |